MATE TRANSPORTERS: INVOLVEMENT IN DRUG PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS
- Authors: Evteev V.A.1, Prokof'ev A.B.1,2, Bunyatyan N.D.1,2, Kukes V.G.1
-
Affiliations:
- Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 68, No 7 (2019)
- Pages: 44-47
- Section: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113195
- DOI: https://doi.org/10.29296/25419218-2019-07-08
- ID: 113195
Cite item
Abstract
Keywords
Full Text
About the authors
Vladimir Aleksandrovich Evteev
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: pharmchemist@gmail.com
senior analyst, department of Personalized Medicine and Clinical Pharmacogetics 8, Petrovsky Boulevard, Build. 2, Moscow 127051, Russian Federation
Aleksej Borisovich Prokof'ev
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: prokofyev56@gmail.com
Director of the Clinical Pharmacology Center; Professor of the Department of Clinical Pharmacology and Internal Medicine Propedeutics 8, Petrovsky Boulevard, Build. 2, Moscow 127051, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation
Natal'ya Dmitrievna Bunyatyan
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: ndbun@mail.ru
Chief analyst of the Clinical Pharmacology Center; Head of the Department of Pharmaceutical Technology and Pharmacology 8, Petrovsky Boulevard, Build. 2, Moscow 127051, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation
Vladimir Grigor'evich Kukes
Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation
Email: elmed@yandex.ru
Scientific Consultant Clinical Pharmacology Center, Doctor of Medical Sciences, professor 8, Petrovsky Boulevard, Build. 2, Moscow 127051, Russian Federation
References
- Terada T. et al. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm. Res., 2006; 23(8): 1696-701.
- Masuda S.et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 2006; 17 (8): 2127-35.
- Lu M1., Symersky J., Radchenko M. et al. Structures of a Na+-coupled, substrate-bound MATE multidrug transporter. Proc. Natl. Acad. Sci.USA., 2013; 110 (6): 2099-104.
- Tsuda M.et al. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am. J. Physiol. Renal. Physiol., 2007; 292 (2): 593-8.
- Tanihara Y. et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol., 2007; 74 (2): 359-71.
- Sato T., Masuda S., Yonezawa A.et al. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem. Pharmacol., 2008;76: 894-903.
- Tsuda M. et al. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol., 2009; 75 (6): 1280-6.
- Nakamura T. et al. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol., 2010; 80 (11): 1762-67.
- Tsuda M. et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther., 2009; 329 (1): 185-91.
- Yonezawa A., InuiK. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br. J. Pharmacol., 2011; 164 (7): 1817-25.
- Kusuhara H. et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin. Pharmacol. Ther., 2011; 89 (6): 837-44.
- Cho S.K., Chung J.Y. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment. Int. J. Clin. Pharmacol. Ther., 2016; 54 (4): 253-62.
- He R. et al., SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res. Clin. Pract., 2015; 109 (1): 57-63.
- Tkac I. et al., Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes. Metab., 2013; 15(2): 189-91.
- Tsuda M. et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther., 2009; 329(1): 185-191.
- Kusuhara H. et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin. Pharmacol. Ther., 2011; 89(6): 837-844.
- Oh J. et al. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans. Diabetes Obes. Metab., 2016; 18(1): 104-108.
- Li Q. et al. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol. Appl. Pharmacol., 2013; 273(1): 100-109.
- Hillgren K.M. et al. Emerging transporters of clinical importance: an update from the international transporter consortium. Clin. Pharmacol. Ther., 2013; 94(1): 52-63.
- Букатина Т.М., Пастернак Е.Ю., Романов Б.К. и др. Рекомендации зарубежных регуляторных органов. Безопасность и риск фармакотерапии. 2016; 4: 31-40